Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
Friends of Cancer Research's 2013 Annual Report is now available for download.
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
JCAR015 - (Juno Therapeutics)
for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia
Dupilumab - (Regeneron and Sanofi)
for the treatment of atopic dermatitis
SPK-RPE65 - (Spark Therapeutics)
for the treatment of inherited retinal dystrophies (IRDs) caused by autosomal recessive mutations in the RPE65 gene
Leaders from advocacy, industry and government share their thoughts on the impact of Lung-MAP, a recently launched innovative clinical trial for lung cancer.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700